Rapid-acting antidepressant strategies: Mechanisms of action

International Journal of Neuropsychopharmacology

Volumn 15, Issue 5, 2012, Pages 695-713

  Bunney, Blynn G ^a   Bunney, William E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Depression; ketamine; rapid acting antidepressants; sleep deprivation therapy

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; CLOMIPRAMINE; FLUVOXAMINE; KETAMINE; LITHIUM; MAPROTILINE; NORTRIPTYLINE; PAROXETINE; PINDOLOL; SERTRALINE; VALPROIC ACID;

CIRCADIAN RHYTHM SLEEP DISORDER; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; PHOTOTHERAPY; PRIORITY JOURNAL; REVIEW; SLEEP DEPRIVATION; SLEEP THERAPY; UNITED STATES;

DEPRESSIVE DISORDER; HUMANS; KETAMINE; SLEEP DEPRIVATION; TIME FACTORS;

EID: 84861070414     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000927     Document Type: Review

References (191)

1. Aan het Rot M, Collins KA, Murrough JW, Perez AM, et al.(2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry.67.139-145.
2. Abe M, Herzog ED, Block GD (2000). Lithium lengthens the circadian period of individual suprachiasmatic nucleus neurons. Neuroreport 11, 3261-3264.
3. Abe H, Rusak B, Robertson HA (1992). NMDA and non-NMDA receptor antagonists inhibit photic induction of Fos protein in the hamster suprachiasmatic nucleus. Brain Research Bulletin 28, 831-835.
4. Alt A, Witkin JM, Bleakman D (2005). AMPA receptor potentiators as novel antidepressants. Current Pharmaceutical Design 11, 1511-1527. (Pubitemid 40691449)
5. Ampuero E, Rubio FJ, Falcon R, Sandoval M, et al. (2010). Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience 169, 98-108.
6. Avery DH, Shah SH, Eder DN, Wildschiodtz G (1999). Nocturnal sweating and temperature in depression. Acta Psychiatrica Scandinavica 100, 295-301. (Pubitemid 29428385)
7. Baxter LR (1985). Can lithium carbonate prolong the antidepressant effect of sleep deprivation? Archives of General Psychiatry 42, 635.
8. Baxter LR, Liston EH, Schwartz JM, Altshuler LL, et al. (1986). Prolongation of the antidepressant response to partial sleep deprivation by lithium. Psychiatry Research 19, 17-23. (Pubitemid 16021810)
9. Benca R, Duncan MJ, Frank E, McClung C, et al. (2009). Biological rhythms, higher brain function, and behavior: gaps, opportunities, and challenges. Brain Research Reviews 62, 57-70.
10. Benedetti F, Barbini B, Bernasconi A, Fulgosi MC, et al. (2008). Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation. Journal of Clinical Psychopharmacology 28, 249-251. (Pubitemid 351417139)
11. Benedetti F, Barbini B, Campori E, Fulgosi MC, et al. (2001). Sleep phase advance and lithium to sustain the antidepressant effect of total sleep deprivation in bipolar depression: new findings supporting the internal coincidence model? Journal of Psychiatric Research 35, 323-329. (Pubitemid 33000469)
12. Benedetti F, Barbini B, Colombo C, Smeraldi E (2007a). Chronotherapeutics in a psychiatric ward. Sleep Medicine Reviews 11, 509-522. (Pubitemid 350087710)
13. Benedetti F, Barbini B, Fulgosi MC, Colombo C, et al. (2005). Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. Journal of Clinical Psychiatry 66, 1535-1540. (Pubitemid 43068692)
14. Benedetti F, Colombo C, Barbini B, Campori E, et al. (1999). Ongoing lithium treatment prevents relapse after total sleep deprivation. Journal of Clinical Psychopharmacology 19, 240-245. (Pubitemid 29233018)
15. Benedetti F, Dallaspezia S, Fulgosi MC, Barbini B, et al. (2007b). Phase advance is an actimetric correlate of antidepressant response to sleep deprivation and light therapy in bipolar depression. Chronobiology International 24, 921-937. (Pubitemid 350125650)
16. Benedetti F, Dallaspezia S, Fulgosi MC, Lorenzi C, et al. (2007c). Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics 144, 631-635. (Pubitemid 47077147)
17. Benedetti F, Lucca A, Brambilla F, Colombo C, et al. (2002). Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance. Progress in Neuropsychopharmacology & Biological Psychiatry 26, 1167-1170. (Pubitemid 35256111)
18. Benedetti F, Serretti A, Colombo C, Lilli R, et al. (2003). Dopamine receptor D2 and D3 gene variants are not associated with the antidepressant effect of total sleep deprivation in bipolar depression. Psychiatry Research 118, 241-247. (Pubitemid 36776652)
19. Berman RM, Cappiello A, Anand A, Oren DA, et al. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47, 351-354. (Pubitemid 30109248)
20. Bjerre J, Fontenay C (2010). Ketamine in melancholic depression. Ugeskrift for Laeger 172, 460-461.
21. Buckley TM, Schatzberg AF (2010). A pilot study of the phase angle between cortisol and melatonin in major depression-a potential biomarker? Journal of Psychiatric Research 44, 69-74.
22. Bump GM, Reynolds 3rd CF, Smith G, Pollock BG, et al. (1997). Accelerating response in geriatric depression: a pilot study combining sleep deprivation and paroxetine. Depression and Anxiety 6, 113-118. (Pubitemid 28079898)
23. Bunney JN, Potkin SG (2008). Circadian abnormalities, molecular clock genes and chronobiological treatments in depression. British Medical Bulletin 86, 23-32. (Pubitemid 351809636)
24. Bunney WE, Bunney BG (2000). Molecular clock genes in man and lower animals : possible implications for circadian abnormalities in depression. Neuropsychopharmacology 22, 335-345. (Pubitemid 30105762)
25. Caliyurt O, Guducu F (2005). Partial sleep deprivation therapy combined with sertraline induces more rapid improvements in quality of life items in major depressive disorder. Journal of Affective Disorders 88, 75-78. (Pubitemid 41160416)
26. Campbell SS, Gillin JC, Kripke DF, Janowsky DS, et al. (1989). Lithium delays circadian phase of temperature and REM sleep in a bipolar depressive: a case report. Psychiatry Research 27, 23-29. (Pubitemid 19042422)
27. Cao R, Lee B, Cho HY, Saklayen S, et al. (2008). Photic regulation of the mTOR signaling pathway in the suprachiasmatic circadian clock. Molecular Cell Neuroscience 38, 312-324.
28. Cao R, Li A, Cho HY, Lee B, et al. (2010). Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock. Journal of Neuroscience 30, 6302-6314.
29. Cao R, Obrietan K (2010). mTOR signaling and entrainment of the mammalian circadian clock. Molecular Cell Pharmacology 2, 125-130.
30. Carpenter Jr. WT, Bunney Jr. WE (1971). Adrenal cortical activity in depressive illness. American Journal of Psychiatry 128, 31-40.
31. Chambille I (1999). Circadian rhythm of AMPA receptor GluR2/3 subunit-immunoreactivity in the suprachiasmatic nuclei of Syrian hamster and effect of a light-dark cycle. Brain Research 833, 27-38. (Pubitemid 29336142)
32. Chassard D, Duflo F, de Queiroz Siqueira M, Allaouchiche B, et al. (2007). Chronobiology and anaesthesia. Current Opinion in Anaesthesiology 20, 186-190. (Pubitemid 46701329)
33. Clark C, Dupont R, Golshan S, Gillin JC, et al. (2000). Preliminary evidence of an association between increased REM density and poor antidepressant response to partial sleep deprivation. Journal of Affective Disorders 59, 77-83. (Pubitemid 30256242)
34. Clark CP, Brown GG, Frank L, Thomas L, et al. (2006). Improved anatomic delineation of the antidepressant response to partial sleep deprivation in medial frontal cortex using perfusion-weighted functional MRI. Psychiatry Research 146, 213-222. (Pubitemid 43782730)
35. Clark CP, Frank LR, Brown GG (2001). Sleep deprivation, EEG, and functional MRI in depression: preliminary results. Neuropsychopharmacology 25 (Suppl. 5), S79-S84. (Pubitemid 33000274)
36. Claustrat B, Chazot G, Brun J, Jordan D, et al. (1984). A chronobiological study of melatonin and cortisol secretion in depressed subjects : plasma melatonin, a biochemical marker in major depression. Biological Psychiatry 19, 1215-1228. (Pubitemid 14014784)
37. Clements JA, Nimmo WS (1981). Pharmacokinetics and analgesic effect of ketamine in man. British Journal of Anaesthesiology 53, 27-30. (Pubitemid 11210925)
38. Colombo C, Benedetti F, Barbini B, Campori E, et al. (1999). Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. Psychiatry Research 86, 267-270. (Pubitemid 29393049)
39. Colombo C, Lucca A, Benedetti F, Barbini B, et al. (2000). Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction. Psychiatry Research 95, 43-53. (Pubitemid 30445203)
40. Colwell CS, Menaker M (1992). NMDA as well as non-NMDA receptor antagonists can prevent the phase-shifting effects of light on the circadian system of the golden hamster. Journal of Biological Rhythms 7, 125-136.
41. Correll GE, Futter GE (2006). Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Medicine 7, 92-95. (Pubitemid 43337717)
42. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, et al. (2010a). A randomized add-on trial of an N-methyl-Daspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 67, 793-802.
43. Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, et al. (2010b). Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 71, 1605-1611.
44. Drevets WC, Furey ML (2010). Replication of scopolamine's antidepressant efficacy in major depressive disorder : a randomized, placebo-controlled clinical trial. Biological Psychiatry 67, 432-438.
45. Duncan Jr. WC (1996). Circadian rhythms and the pharmacology of affective illness. Pharmacology and Therapeutics 71, 253-312. (Pubitemid 26366375)
46. Dzirasa K, Coque L, Sidor MM, Kumar S, et al. (2010). Lithium ameliorates nucleus accumbens phase-signaling dysfunction in a genetic mouse model of mania. Journal of Neuroscience 30, 16314-16323.
47. Ebert D, Feistel H, Barocka A (1991). Effects of sleep deprivation on the limbic system and the frontal lobes in affective disorders : a study with Tc-99 m-HMPAO SPECT. Psychiatry Research 40, 247-251.
48. Eide EJ, Kang H, Crapo S, Gallego M, et al. (2005). Casein kinase I in the mammalian circadian clock. Methods in Enzymology 393, 408-418. (Pubitemid 40486536)
49. Elsenga S, van den Hoofdakker RH (1982). Clinical effects of sleep deprivation and clomipramine in endogenous depression. Journal of Psychiatric Research 17, 361-374. (Pubitemid 14249824)
50. Elsenga S, Van den Hoofdakker RH (1987). Response to total sleep deprivation and clomipramine in endogenous depression. Journal of Psychiatric Research 21, 151-161. (Pubitemid 17121248)
51. Emens J, Lewy A, Kinzie JM, Arntz D, et al. (2009). Circadian misalignment in major depressive disorder. Psychiatry Research 168, 259-261.
52. Fleming JJ, England PM (2010). AMPA receptors and synaptic plasticity: a chemist's perspective. Nature Chemical Biology 6, 89-97.
53. Fritzsche M, Heller R, Hill H, Kick H (2001). Sleep deprivation as a predictor of response to light therapy in major depression. Journal of Affective Disorders 62, 207-215. (Pubitemid 32167087)
54. Furey ML, Drevets WC (2006). Antidepressant efficacy of the antimuscarinic drug scopolamine : a randomized, placebo-controlled clinical trial. Archives of General Psychiatry 63, 1121-1129. (Pubitemid 44498391)
55. Galecki P, Szemraj J, Bartosz G, Bienkiewicz M, et al. (2010). Single-nucleotide polymorphisms and mRNA expression for melatonin synthesis rate-limiting enzyme in recurrent depressive disorder. Journal of Pineal Research 48, 311-317.
56. Gelenberg AJ, Chesen CL (2000). How fast are antidepressants? Journal of Clinical Psychiatry 61, 712-721.
57. Gelenberg AJ, Chesen CL (2010). Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd edn. American Psychiatric Association (http://www. psych. org/guidelines/mdd2010).
58. Giedke H, Schwarzler F (2002). Therapeutic use of sleep deprivation in depression. Sleep Medicine Reviews 6, 361-377. (Pubitemid 36529360)
59. Goforth HW, Holsinger T (2007). Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. Journal of ECT 23, 23-25. (Pubitemid 46673528)
60. Gouin JP, Connors J, Kiecolt-Glaser JK, Glaser R, et al. (2010). Altered expression of circadian rhythm genes among individuals with a history of depression. Journal of Affective Disorders 126, 161-166.
61. Hashimoto K (2010). The role of glutamate on the action of antidepressants. Progress in Neuro-psychopharmacology & Biological Psychiatry. Published online : 20 June 2010. doi : 10. 1016/j. pnpbp. 2010. 06. 013.
62. Hasler BP, Buysse DJ, Kupfer DJ, Germain A (2010). Phase relationships between core body temperature, melatonin, and sleep are associated with depression severity : further evidence for circadian misalignment in non-seasonal depression. Psychiatry Research 178, 205-207.
63. Haug HJ (1992). Prediction of sleep deprivation outcome by diurnal variation of mood. Biological Psychiatry 31, 271-278.
64. Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG (2005). 5-HT7 receptor inhibition and inactivation induce antidepressant-like behavior and sleep pattern. Biological Psychiatry 58, 831-837. (Pubitemid 41677422)
65. Hempelmann G, Kuhn DF (1997). Clinical significance of S-(+)-ketamine. Anaesthesist 46 (Suppl. 1), S3-S7.
66. Holsboer-Trachsler E, Hemmeter U, Hatzinger M, Seifritz E (1994). Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment-neurobiological and psychometric assessment of course. Journal of Psychiatric Research 28, 381-399. (Pubitemid 24370025)
67. Holthoff VA, Beuthien-Baumann B, Pietrzyk U, Pinkert J, et al. (1999). Changes in regional cerebral perfusion in depression. SPECT monitoring of response to treatment. Nervenarzt 70, 620-626. (Pubitemid 29336784)
68. Holtzheimer III PE, McDonald WM, Mufti M, Kelley ME, et al. (2010). Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. Depression & Anxiety 27, 960-963.
69. Insel TR, Scolnick EM (2006). Cure therapeutics and strategic prevention: raising the bar for mental health research. Molecular Psychiatry 11, 11-17. (Pubitemid 43251083)
70. Ishida N, Matsui M, Mitsui Y, Mishina M (1994). Circadian expression of NMDA receptor mRNAs, epsilon 3 and zeta 1, in the suprachiasmatic nucleus of rat brain. Neuroscience Letters 166, 211-215.
71. Jarrett DB, Miewald JM, Kupfer DJ (1988). Acute changes in sleep-related hormone secretion of depressed patients following oral imipramine. Biological Psychiatry 24, 541-554.
72. Jick H, Kaye JA, Jick SS (2004). Antidepressants and the risk of suicidal behaviors. Journal of the American Medical Association 292, 338-343. (Pubitemid 38944257)
73. Johnsson A, Engelmann W, Pflug B, Klemke W (1983). Period lengthening of human circadian rhythms by lithium carbonate, a prophylactic for depressive disorders. International Journal of Chronobiology 8, 129-147.
74. Judd LL, Akiskal HS, Schettler PJ, Endicott J, et al. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 59, 530-537. (Pubitemid 34602935)
75. Kaladchibachi SA, Doble B, Anthopoulos N, Woodgett JR, et al. (2007). Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder : a molecular link in the therapeutic action of lithium. Journal of Circadian Rhythms 5, 3.
76. Kasper S, Kick H, Voll G, Vieira A (1991). Therapeutic sleep deprivation and antidepressant medication in patients with major depression. European Neuropsychopharmacology 1, 107-111.
77. Kasper S, Voll G, Vieira A, Kick H (1990). Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression-results of a double-blind study. Pharmacopsychiatry 23, 135-142. (Pubitemid 20304127)
78. Kennaway DJ (2010). Clock genes at the heart of depression. Journal of Psychopharmacology 24 (Suppl. 2), 5-14.
79. Kennedy SH, Evans KR, Kruger S, Mayberg HS, et al. (2001). Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. American Journal of Psychiatry 158, 899-905. (Pubitemid 32547619)
80. Knapp RJ, Goldenberg R, Shuck C, Cecil A, et al. (2002). Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. European Journal of Pharmacology 440, 27-35. (Pubitemid 34312035)
81. Koenigsberg HW, Teicher MH, Mitropoulou V, Navalta C, et al. (2004). 24-h Monitoring of plasma norepinephrine, MHPG, cortisol, growth hormone and prolactin in depression. Journal of Psychiatry Research 38, 503-511. (Pubitemid 39221758)
82. Kohrs R, Durieux ME (1998). Ketamine : teaching an old drug new tricks. Anesthesiology & Analgesia 87, 1186-1193. (Pubitemid 28501183)
83. Kripke DF (1984). Critical interval hypotheses for depression. Chronobiology International 1, 73-80. (Pubitemid 14016470)
84. Kripke DF, Nievergelt CM, Joo E, Shekhtman T, et al. (2009). Circadian polymorphisms associated with affective disorders. Journal of Circadian Rhythms 7, 2.
85. Kuhs H, Farber D, Borgstadt S, Mrosek S, et al. (1996). Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. Journal of Affective Disorders 37, 31-41. (Pubitemid 26072814)
86. Kuhs H, Kemper B, Lippe-Neubauer U, Meyer-Dunker J, et al. (1998). Repeated sleep deprivation once versus twice a week in combination with amitriptyline. Journal of Affective Disorders 47, 97-103. (Pubitemid 28066764)
87. Kupfer DJ (1976). REM latency : a psychobiologic marker for primary depressive disease. Biological Psychiatry 11, 159-174.
88. Lam RW, Kripke DF, Gillin JC (1989). Phototherapy for depressive disorders: a review. Canadian Journal of Psychiatry 34, 140-147. (Pubitemid 19193258)
89. Landsness EC, Goldstein MR, Peterson MJ, Tononi G, et al. (2011). Antidepressant effects of selective slow wave sleep deprivation in major depression: a high-density EEG investigation. Journal of Psychiatric Research. Published online 3 March 2011. doi:10. 1016/j. jpsychires. 2011. 02. 003.
90. Lavebratt C, Sjoholm LK, Partonen T, Schalling M, et al. (2010a). PER2 variation is associated with depression vulnerability. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 153B, 570-581.
91. Lavebratt C, Sjoholm LK, Soronen P, Paunio T, et al. (2010b). CRY2 is associated with depression. PLoS One 5, e9407.
92. Leibenluft E, Moul DE, Schwartz PJ, Madden PA, et al. (1993). A clinical trial of sleep deprivation in combination with antidepressant medication. Psychiatry Research 46, 213-227. (Pubitemid 23121523)
93. Lewy AJ (2010). Depressive disorders may more commonly be related to circadian phase delays rather than advances: time will tell. Sleep Medicine 11, 117-118.
94. Lewy AJ, Cutler NL, Sack RL (1999). The endogenous melatonin profile as a marker for circadian phase position. Journal of Biological Rhythms 14, 227-236. (Pubitemid 30157102)
95. Lewy AJ, Nurnberger Jr. JI, Wehr TA, Pack D, et al. (1985). Supersensitivity to light : possible trait marker for manic-depressive illness. American Journal of Psychiatry 142, 725-727. (Pubitemid 15024564)
96. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, et al. (1981). Manic-depressive patients may be supersensitive to light. Lancet 1, 383-384.
97. Li N, Lee B, Liu RJ, Banasr M, et al. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964.
98. Liebrenz M, Borgeat A, Leisinger R, Stohler R (2007). Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Medical Weekly, 137, 234-236. (Pubitemid 46814243)
99. Liebrenz M, Stohler R, Borgeat A (2009). Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World Journal of Biological Psychiatry 10, 640-643.
100. Loving RT, Kripke DF, Knickerbocker NC, Grandner MA (2005). Bright green light treatment of depression for older adults [ISRCTN69400161]. BMC Psychiatry 5, 42.
101. Loving RT, Kripke DF, Shuchter SR (2002). Bright light augments antidepressant effects of medication and wake therapy. Depression and Anxiety 16, 1-3. (Pubitemid 34977119)
102. Lucas G, Du J, Romeas T, Mnie-Filali O, et al. (2010). Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat. PLoS One 5, e9253.
103. Lucas G, Rymar VV, Du J, Mnie-Filali O, et al. (2007). Serotonin. (5-HT). receptor agonists are putative antidepressants with a rapid onset of action. Neuron 55, 712-725. (Pubitemid 47334877)
104. Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, et al. (2009). Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. Journal of Clinical Psychiatry 70, 1662-1666.
105. Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, et al. (2008). Rapid onset of antidepressant action : a new paradigm in the research and treatment of major depressive disorder. Journal of Clinical Psychiatry 69, 946-958. (Pubitemid 351944948)
106. Malhotra AK, Pinals DA, Adler CM, Elman I, et al. (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17, 141-150. (Pubitemid 27365955)
107. Mathew SJ, Manji HK, Charney DS (2008). Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 33, 2080-2092. (Pubitemid 351992096)
108. Mathew SJ, Murrough JW, aan het Rot M, Collis KA, et al. (2010). Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. International Journal of Neuropsychopharmacology 13, 71-82.
109. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, et al. (1997). Cingulate function in depression: a potential predictor of treatment response. Neuroreport 8, 1057-1061. (Pubitemid 27152174)
110. McClung CA (2007). Circadian genes, rhythms and the biology of mood disorders. Pharmacology & Therapeutics 114, 222-232. (Pubitemid 46561535)
111. McIntyre IM, Judd FK, Marriott PM, Burrows GD, et al. (1989). Plasma melatonin levels in affective states. International Journal of Clinical Pharmacological Research 9, 159-164. (Pubitemid 19095798)
112. Mendlewicz J (2009a). Disruption of the circadian timing systems: molecular mechanisms in mood disorders. CNS Drugs 23 (Suppl. 2), 15-26.
113. Mendlewicz J (2009b). Sleep disturbances : core symptoms of major depressive disorder rather than associated or comorbid disorders. World Journal of Biological Psychiatry 10, 269-275.
114. Messer M, Haller IV, Larson P, Pattison-Crisostomo et al. (2010). The use of a series of ketamine infusions in two patients with treatment-resistant depression. Journal of Neuropsychiatry & Clinical Neuroscience 22, 442-444.
115. Mnie-Filali O, Faure C, Lambas-Senas L, Mansari ME, et al. (2011). Pharmacological blockade of 5-HT. receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 36, 1275-1288.
116. Morris DW, Trivedi MH, Fava M, Wisniewski SR, et al. (2009). Diurnal mood variation in outpatients with major depressive disorder. Depression and Anxiety 26, 851-863.
117. Moscovici L, Kotler M (2009). A multistage chronobiologic intervention for the treatment of depression: a pilot study. Journal of Affective Disorders 116, 201-207.
118. Mukherjee S, Coque L, Cao JL, Kumar J, et al. (2010). Knockdown of Clock in the ventral tegmental area through RNA interference results in a mixed state of mania and depression-like behavior. Biological Psychiatry 68, 503-511.
119. Nagayama H (1996). Chronic administration of imipramine and lithium changes the phase-angle relationship between the activity and core body temperature circadian rhythms in rats. Chronobiology International 13, 251-259. (Pubitemid 26379485)
120. Nair NP, Hariharasubramanian N, Pilapil C (1984). Circadian rhythm of plasma melatonin in endogenous depression. Progress in Neuropsychopharmacology & Biological Psychiatry 8, 715-718. (Pubitemid 15193233)
121. Nathan PJ, Burrows GD, Norman TR (1999). Melatonin sensitivity to dim white light in affective disorders. Neuropsychopharmacology 21, 408-413. (Pubitemid 29333079)
122. Nemeroff CB (2004). Early-life adversity, CRF dysregulation, and vulnerability to mood and anxiety disorders. Psychopharmacology Bulletin 38 (Suppl. 1), 14-20.
123. Neumeister A, Goessler R, Lucht M, Kapitany T, et al. (1996). Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. Biological Psychiatry 39, 16-21. (Pubitemid 26024198)
124. NIMH (2010). Rapidly-acting treatments for treatmentresistant depression (RAPID) (https://www. fbo. gov/index?s=opportunity&mode=form&id= b60ff8d1fc48206436a732b38b92614a&tab= core&-cview=1).
125. NIMH (2011). Any mood disorder among adults (http://wwwapps. nimh. nih. gov/health/publications/thenumbers-count-mental-disorders-in-america. shtml).
126. Ohdo S (2010). Chronopharmaceutics: pharmaceutics focused on biological rhythm. Biological & Pharmacological Bulletin 33, 159-167.
127. Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M (2010). Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 43, 33-35.
128. Paul KN, Fukuhara C, Karom M, Tosini G, et al. (2005). AMPA/kainate receptor antagonist DNQX blocks the acute increase of Per2 mRNA levels in most but not all areas of the SCN. Brain Research. Molecular Brain Research 139, 129-136. (Pubitemid 41583595)
129. Paul KN, Fukuhara C, Tosini G, Albers HE (2003). Transduction of light in the suprachiasmatic nucleus: evidence for two different neurochemical cascades regulating the levels of Per1 mRNA and pineal melatonin. Neuroscience 119, 137-144. (Pubitemid 36577417)
130. Paul R, Schaaff N, Padberg F, Moller HJ, et al. (2009). Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World Journal of Biological Psychiatry 10, 241-244.
131. Pflug B, Tolle R (1971). Disturbance of the 24-hour rhythm in endogenous depression and the treatment of endogenous depression by sleep deprivation. International Pharmacopsychiatry 6, 187-196.
132. Popik P, Kos T, Sowa-Kucma M, Nowak G (2008). Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berlin) 198, 421-430.
133. Posternak MA, Zimmerman M (2005). Is there a delay in the antidepressant effect? A meta-analysis. Journal of Clinical Psychiatry 66, 148-158. (Pubitemid 40314320)
134. Pouget P, Wattiez N, Rivaud-Pechoux S, Gaymard B (2010). Rapid development of tolerance to sub-anaesthetic dose of ketamine: an oculomotor study in macaque monkeys. Psychopharmacology (Berlin) 209, 313-318.
135. Price RB, Nock MK, Charney DS, Mathew SJ (2009). Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biological Psychiatry 66, 522-526.
136. Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, et al. (1995). Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology 118, 385-390.
137. Raeder JC, Stenseth LB (2000). Ketamine: a new look at an old drug. Current Opinion in Anaesthesiology 13, 463-468. (Pubitemid 30623806)
138. Riemann D, Berger M, Voderholzer U (2001). Sleep and depression-results from psychobiological studies : an overview. Biological Psychology 57, 67-103. (Pubitemid 32651895)
139. Riemann D, Konig A, Hohagen F, Kiemen A, et al. (1999). How to preserve the antidepressive effect of sleep deprivation: a comparison of sleep phase advance and sleep phase delay. European Archives of Psychiatry and Clinical Neuroscience 249, 231-237. (Pubitemid 29537525)
140. Roybal K, Theobold D, Graham A, DiNieri JA, et al. (2007). Mania-like behavior induced by disruption of CLOCK. Proceedings of the National Academy of Sciences USA 104, 6406-6411. (Pubitemid 47186107)
141. Rudolf GA, Tolle R (1978). Sleep deprivation and circadian rhythm in depression. Psychiatric Clinics (Basel) 11, 198-212. (Pubitemid 9174858)
142. Rush AJ, Trivedi M, Fava M (2003). Depression, IV: STAR*D treatment trial for depression. American Journal of Psychiatry 160, 237.
143. Sack DA, Nurnberger J, Rosenthal NE, Ashburn E, et al. (1985). Potentiation of antidepressant medications by phase advance of the sleep-wake cycle. American Journal of Psychiatry 142, 606-608. (Pubitemid 15034631)
144. Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, et al. (2009). Increased anterior cingulate cortical activity in response to fearful faces : a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biological Psychiatry 65, 289-295.
145. Salvadore G, Cornwell BR, Sambataro F, Latov D, et al. (2010). Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35, 1415-1422.
146. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 7, 426-437. (Pubitemid 351619114)
147. Scharnholz B, Lederbogen F, Feuerhack A, Bach A, et al. (2010). Does night-time cortisol excretion normalize in the long-term course of depression? Pharmacopsychiatry 43, 161-165.
148. Schulte W (ed. ) (1966). Kombinierte psycho-und pharmakotherapie bei melancholikern. In Probleme Pharmakopsychiarrischer Kombination und Langzeir Behandlungen. Basel, New York: Karger.
149. Seggie J (1988). Lithium and the retina. Progress in Neuropsychopharmacology & Biological Psychiatry 12, 241-253.
150. Seggie J, Canny C, Mai F, McCrank E, et al. (1989). Antidepressant medication reverses increased sensitivity to light in depression: preliminary report. Prog Neuropsychopharmacology & Biological Psychiatry 13, 537-541. (Pubitemid 19163804)
151. Shelton RC, Loosen PT (1993). Sleep deprivation accelerates the response to nortriptyline. Progress in Neuropsychopharmacology & Biological Psychiatry 17, 113-123.
152. Shimomura K, Lowrey PL, Vitaterna MH, Buhr ED, et al. (2010). Genetic suppression of the circadian Clock mutation by the melatonin biosynthesis pathway. Proceedings of the National Academy of Sciences USA 107, 8399-8403.
153. Sjoholm LK, Backlund L, Cheteh EH, Ek IR, et al. (2010). CRY2 is associated with rapid cycling in bipolar disorder patients. PLoS One 5, e12632.
154. Skene DJ, Bojkowski CJ, Arendt J (1994). Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. British Journal of Clinical Pharmacology 37, 181-186. (Pubitemid 24213760)
155. Smeraldi E, Benedetti F, Barbini B, Campori E, et al. (1999). Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial. Neuropsychopharmacology 20, 380-385. (Pubitemid 29099769)
156. Smith GS, Reynolds III CF, Houck PR, Dew MA, et al. (2002). Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. American Journal Geriatric Psychiatry 10, 561-567. (Pubitemid 34984392)
157. Smith GS, Reynolds III CF, Pollock B, Derbyshire S (1999). Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. American Journal of Psychiatry 156, 683-689. (Pubitemid 29220064)
158. Sokolski KN, Reist C, Chen CC, DeMet EM (1995). Antidepressant responses and changes in visual adaptation after sleep deprivation. Psychiatry Research 57, 197-207.
159. Soria V, Martinez-Amoros E, Escaramis G, Valero J, et al. (2010a). Resequencing and association analysis of arylalkylamine N-acetyltransferase (AANAT). Gene and its contribution to major depression susceptibility. Journal of Pineal Research 49, 35-44.
160. Soria V, Martinez-Amoros E, Escaramis G, Valero J, et al. (2010b). Differential association of circadian genes with mood disorders : CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology 35, 1279-1289.
161. Souetre E, Salvati E, Pringuey D, Plasse Y, et al. (1987). Antidepressant effects of the sleep/wake cycle phase advance. Preliminary report. Journal of Affective Disorders 12, 41-46. (Pubitemid 17047122)
162. Souetre E, Salvati E, Wehr TA, Sack DA (1988). Twenty-four-hour profiles of body temperature and plasma TSH in bipolar patients during depression and during remission and in normal control subjects. American Journal of Psychiatry 145, 1133-1137.
163. Sprouse J, Braselton J, Reynolds L (2006). Fluoxetine modulates the circadian biological clock via phase advances of suprachiasmatic nucleus neuronal firing. Biological Psychiatry 60, 896-899. (Pubitemid 44527886)
164. Szuba MP, Baxter Jr. LR, Altshuler LL, Allen EM, et al. (1994). Lithium sustains the acute antidepressant effects of sleep deprivation: preliminary findings from a controlled study. Psychiatry Research 51, 283-295. (Pubitemid 24104417)
165. Takahashi JS (2004). Finding new clock components : past and future. Journal of Biological Rhythms 19, 339-347. (Pubitemid 39238203)
166. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 28-40. (Pubitemid 43050100)
167. Uher R, Maier W, Hauser J, Marusic A, et al. (2009). Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. British Journal of Psychiatry 194, 252-259.
168. Utge SJ, Soronen P, Loukola A, Kronholm E, et al. (2010). Systematic analysis of circadian genes in a population-based sample reveals association of TIMELESS with depression and sleep disturbance. PLoS One 5, e9259.
169. Van den Burg W, Bouhuys AL, van den Hoofdakker RH, Beersma DG (1990). Sleep deprivation in bright and dim light : antidepressant effects on major depressive disorder. Journal of Affective Disorders 19, 109-117. (Pubitemid 20178779)
170. Voderholzer U, Valerius G, Schaerer L, Riemann D, et al. (2003). Is the antidepressive effect of sleep deprivation stabilized by a three day phase advance of the sleep period? A pilot study. European Archives of Psychiatry & Clinical Neuroscience 253, 68-72. (Pubitemid 37205479)
171. Vogel GW (1975). A review of REM sleep deprivation. Archives of General Psychiatry 32, 749-761.
172. Volk S, Kaendler SH, Weber R, Georgi K, et al. (1992). Evaluation of the effects of total sleep deprivation on cerebral blood flow using single photon emission computerized tomography. Acta Psychiatrica Scandinavica 86, 478-483.
173. Wang Y, Barbaro MF, Baraban SC (2006). A role for the mTOR pathway in surface expression of AMPA receptors. Neuroscience Letters 401, 35-39.
174. Wehr TA, Rosenthal NE, Sack DA, Gillin JC (1985). Antidepressant effects of sleep deprivation in bright and dim light. Acta Psychiatrica Scandinavica 72, 161-165. (Pubitemid 16240921)
175. Wehr TA, Sack D, Rosenthal N, Duncan W, et al. (1983). Circadian rhythm disturbances in manic-depressive illness. Federation Proceedings 42, 2809-2814. (Pubitemid 13039372)
176. Wehr TA, Wirz-Justice A, Goodwin FK, Duncan W, et al. (1979). Phase advance of the circadian sleep-wake cycle as an antidepressant. Science 206, 710-713. (Pubitemid 10203225)
177. Wetterberg L, Aperia B, Beck-Friis J, Kjellman BF, et al. (1982). Melatonin and cortisol levels in psychiatric illness. Lancet 2, 100.
178. WHO (2011). World Health Organization, Depression. (http://www. who. int/mental-health/management/depression/definition/en/).
179. Wirz-Justice A (2006). Biological rhythm disturbances in mood disorders. International Clinical Psychopharmacology 21 (Suppl. 1), S11-S15.
180. Wirz-Justice A (2008). Diurnal variation of depressive symptoms. Dialogues in Clinical Neuroscience 10, 337-343.
181. Wirz-Justice A, Benedetti F, Berger M, Lam RW, et al. (2005). Chronotherapeutics (light and wake therapy) in affective disorders. Psychological Medicine 35, 939-944. (Pubitemid 41015692)
182. Wirz-Justice A, Benedetti F, Terman M (2009). Chronotherapeutics for Affective Disorders : A Clinician's Manual for Light and Wake Therapy. Basel : Karger.
183. Wirz-Justice A, Van den Hoofdakker RH (1999). Sleep deprivation in depression: what do we know, where do we go? Biological Psychiatry 46, 445-453. (Pubitemid 29369070)
184. Wu J, Buchsbaum MS, Gillin JC, Tang C, et al. (1999). Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. American Journal Psychiatry 156, 1149-1158. (Pubitemid 29374872)
185. Wu JC, Bunney WE (1990). The biological basis of an antidepressant response to sleep deprivation and relapse : review and hypothesis. American Journal of Psychiatry 147, 14-21. (Pubitemid 20025501)
186. Wu JC, Gillin JC, Buchsbaum MS, Hershey T, et al. (1992). Effect of sleep deprivation on brain metabolism of depressed patients. American Journal of Psychiatry 149, 538-543.
187. Wu JC, Gillin JC, Buchsbaum MS, Schachat C (2008). Sleep deprivation PET correlations of Hamilton symptom improvement ratings with changes in relative glucose metabolism in patients with depression. Journal of Affective Disorders 107, 181-186. (Pubitemid 351288903)
188. Wu JC, Kelsoe JR, Schachat C, Bunney BG, et al. (2009). Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biological Psychiatry 66, 298-301.
189. Yin L, Wang J, Klein PS, Lazar MA (2006). Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science 311, 1002-1005. (Pubitemid 43271727)
190. Zarate Jr. C, Machado-Vieira R, Henter I, Ibrahim L, et al. (2010). Glutamatergic modulators: the future of treating mood disorders? Harvard Review of Psychiatry 18, 293-303.
191. Zarate Jr. CA, Singh JB, Carlson PJ, et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General of Psychiatry 63, 856-864. (Pubitemid 44188478)